Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Simon Property Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.59 (market cap $39.89B), while Simon Property Group Inc trades at $218.81 (market cap $70.94B). The key difference: Simon Property Group Inc is the larger of the two by market cap, and Simon Property Group Inc pays a 4.02% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SPG | |
|---|---|---|
Market Cap | $39.89B | $70.94B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $227.56 |
52-Week Low | $278.09 | $159.93 |
Enterprise Value | $38.15B | $99.42B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Simon Property Group (SPG) trades at $218.77, down 0.43% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 70.59% net income margin and has beaten earnings estimates in three consecutive quarters. Recent news highlights robust Q1 2026 results and a dividend payout of $2.25 for H1-26.
Outlook remains positive due to strong leasing and redevelopment, but risks include high debt levels and e-commerce competition. Analyst consensus is mixed with a $214.40 price target, slightly below current levels, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
